22nd Century Announces Expansion of Cannabis Research Program
07 September 2016 - 12:00AM
Business Wire
Intellectual property portfolio puts 22nd
Century at the forefront of cannabis biotechnology
22nd Century Group, Inc. (NYSE MKT: XXII), a plant
biotechnology company that is a leader in tobacco harm reduction
and cannabis research, announced today that the Company’s
wholly-owned subsidiary, Botanical Genetics LLC, has expanded its
cannabis research program to include multiple new research projects
in support of its core mission, which is to develop proprietary
cannabis strains for important new medicines and commercially
viable agricultural crops. More specifically, Botanical Genetics
is: 1) working to develop proprietary cannabis strains for novel,
safe, and effective medical applications, and 2) developing very
low THC industrial hemp varieties that may be legally grown in the
U.S. and around the world as a commercial agricultural crop.
To inform investors and to generate interest from potential
research and commercial partners, Botanical Genetic has today
launched a new website at www.botanicalgenetics.com. The new
website details Botanical Genetics’ strategy, partners, and
projects in the rapidly evolving cannabis space. The Company’s
primary initiatives include:
1) Botanical Genetics is developing new
technologies to make cannabis plants more amenable to genetic
enhancement and improvement. 2) Botanical Genetics is developing
new methods for the manipulation of cannabis plants to result in
unique cannabinoid profiles in proprietary strains of the plant. 3)
Together with its industry partners, Botanical Genetics is
modifying cannabis plants to produce altered profiles of the major
cannabinoids, leading both to new medical marijuana products and to
new industrial hemp varieties. 4) As previously announced,
Botanical Genetics is developing the means to produce cannabinoids
in tobacco – a plant species that shows great promise as a
biofactory for the production of cannabinoids. 5) Botanical
Genetics is actively involved in several state-based industrial
hemp pilot programs to develop and breed improved varieties of
industrial hemp that are specifically optimized to grow in the
climates of particular U.S. states.
In conducting the Company’s legal cannabis research, Botanical
Genetics operates its own laboratories in New York, sponsors
research activities in Vancouver, Canada, and partners with
universities, commercial laboratories, and hemp/cannabis growers in
an increasing number of U.S. states.
“We are the only company in the United States with the freedom
to use all of the enzyme genes in the cannabis plant that lead to
THC, CBD, CBC, and other important cannabinoids,” explained Henry
Sicignano, III, President and CEO of 22nd Century. “I am proud that
our unique – and growing – intellectual property portfolio puts
22nd Century at the forefront of cannabis biotechnology.”
Acknowledging 22nd Century’s growing influence in the cannabis
technology arena, Dr. Paul Rushton, Vice President for Plant
Biotechnology, and Thomas James, Vice President and General Counsel
of 22nd Century, have been appointed to the advisory committee of
the “iHemp Platform.” The iHemp Platform is a cooperative
association of progressive hemp farmers, industry experts and
university leaders who are working together on the successful
implementation of state and regional industrial hemp pilot
programs.
Dr. Rushton explained, “We have decisive plans to make Botanical
Genetics the U.S. leader in cannabis biotechnology. The medical
marijuana and industrial hemp markets are projected to be worth
billions of dollars in the very near term and we intend to be a
major player in these developing industries.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. Visit www.xxiicentury.com and www.botanicalgenetics.com
for more information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2015, filed on February 18, 2016,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906005928/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2023 to Apr 2024